Embed Size (px)
DESCRIPTION
Baseline and On-Treatment Vital Signs and Laboratory Values in Participants Completing the Trial (n=360) a Nissen SE, et al. JAMA 2008;299:
Citation preview
Flow of Patients Through the Trial
Nissen SE, et al. JAMA 2008;299:1561-73
Baseline Demographic Characteristics and Medications at the Time of Randomization
Nissen SE, et al. JAMA 2008;299:1561-73
Baseline and On-Treatment Vital Signs and Laboratory Values in Participants Completing the Trial (n=360)a
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
Changes in Mean Hemoglobin A1c, Fasting Plasma Glucose Levels, High-Density Lipoprotein Cholesterol, and C-Reactive Protein During the Trial (n = 360)
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
Baseline, Follow-up, and Change From Baseline in Intravascular Ultrasound End Points
Nissen SE, et al. JAMA 2008;299:1561-73
Primary Efficacy Parameter (Percent Atheroma Volume) in Prespecified Subgroups
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
Change From Baseline in Intravascular Ultrasound End Points Using Imputed Values for Noncompleters
Nissen SE, et al. JAMA 2008;299:1561-73
Clinical End Points, Adverse Events, Laboratory Abnormalities, and Reasons for Discontinuing Participation (Safety Population, n = 543)
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
